Lung biopsy Doctors Abroad — Page 4

Dr. Adnan Sayar is a thoracic surgeon at Liv Hospital Vadistanbul in Istanbul. He specializes in robotic and thoracoscopic surgery for lung cancer and complex chest diseases. He holds FETCS certification from the European Board of Thoracic and Cardiovascular Surgery. Dr. Sayar performs tracheal reconstruction, lung transplantation, and pediatric thoracic procedures.

• Served on the Turkish Ministry of Health Lung Transplantation Scientific Committee.
• Completed fellowships at Kyoto University in Japan and the Karolinska Institute in Sweden.
• Treats lung cancer through minimally invasive segmentectomy and pneumonectomy.
• Works at JCI-accredited Liv Hospital, a designated Center of Excellence for robotic surgery.

Medical Fields of Interest 

• Thoracoscopic and Robotic Minimally Invasive Surgery 

• Lung Cancers 

• Trachea Surgery 

• Lung Transplantation 

• Lung Biopsy • Pneumothorax (collapsed lung) 

• Diaphragmatic Surgery • Surgery of Pleural Diseases 

• Pediatric Thoracic Surgery

Education 

• Istanbul University, Istanbul Faculty of Medicine 

•Istanbul Galatasaray High School 

• Primary Education Ankara, Samsun, Izmir 

The doctor completed specialization training in Radiation Oncology at Marmara University Faculty of Medicine from 2012 to 2016. Prior to this, the doctor completed an undergraduate degree in Medicine, taught in English, at the same institution from 2004 to 2011. The doctor has a strong foundation in medical education, beginning with high school education at Sixteen Numbered Shirvan School in Azerbaijan from 1998 to 2004.

Areas of Interests

• Breast cancer
• Lung cancer
• Colorectal cancers
• Gynecological and urogenital cancers
• Molecular Oncology

Education:

• Kızıltepe Anatolian High School 2001
• Dicle University Faculty of Medicine 2007
• Istanbul Medeniyet University Göztepe Training and Research Hospital 2014
• Kartal City Hospital 2021
• Associate Professor of Medical Oncology 2023

Experience:

• Liv Hospital Ulus
• Adıyaman University Training and Research Hospital
• Istanbul Umraniye Training and Research Hospital
• Istanbul Umraniye Training and Research Hospital

Research:

• Phase II, Randomized, Open-Label, Multicenter Study to Comparatively Evaluate the Efficacy and Safety of GDC-9545 and Physician-Preferred Endocrine Monotherapy in Previously Treated, Estrogen Receptor Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer Patients, Other ( International), Dr. Murat Ayhan
• Phase III, Randomized, Evaluating the Efficacy and Safety of Palbociclib and Fulvestrant with Gdc-0077 Compared with Placebo in Patients with Pik3ca-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer. Double Blind, Placebo Controlled Study, Other (International), Dr. Murat Ayhan
• Randomized, Multicenter, Phase Ib/III Study Evaluating the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Atezolizumab Compared to Intravenous Atezolizumab in Patients with Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer, Other (International) Dr. Murat Ayhan
• Randomized, Controlled, Multicenter, Open-Label Study Including Observation Follow-Up for PSMA-PET-Negative Patients, Investigating the Efficacy and Safety of Addition of Apalutamide to Radiotherapy and LHRH Agonist in PSMA-PET-Positive High-Risk Hormone-Sensitive Prostate Cancer Patients, Other (International) Dr. Murat Ayhan
• Biomarker Study to Identify Patients with Advanced Stage Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations-42756493BLC0002, Other (International), Dr. Murat Ayhan
• Publications:
• Ayhan M, Turan N, Köstek O, et all. Does the efficacy of regorafenib differ in chemotherapy refractory metastatic colorectal cancer patients who had mucinous pathology compared to those who had non-mucinous pathology? Curr Probl Cancer. 2021 Jun;45(3):100670. doi: 10.1016/j.currproblcancer.2020.100670.
• Ayhan M, Odabas H, Turan N, et all. Factors affecting the mortality rate of patients with cancer hospitalized with COVID-19: a single center's experience. J Chemother. 2021 Nov;33(7):499-508. doi: 10.1080/1120009X.2021.1923153.
• Ayhan M, Laçin Ş, Özyükseler DT, et all. Does systemic anti-tumor therapy increase COVID-19 risk in patients with cancer? J Oncol Pharm Pract. 2021 Sep;27(6):1461-1467. doi: 10.1177/10781552211015762.
• Ayhan M, Abamor E, Coban Kokten S, et al. Value of FDG PET/CT in Predicting Pathologic Complete Response After Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer. EJMI 2022;6(2):165–175.
• Ayhan M, Terzioglu K. Experience With Rapid Drug Desensitization With Chemotherapeutics; A SingleCentre Retrospective Study. EJMI 2021;5(3):380–387.
• Doğan A, AYHAN M. Survival analysis of patients with triple-negative breast cancer: a single-center experience. Journal of Oncological Sciences, 8(2), 94-99., Doi: 10.37047/jos.2022-89749
• Terzioğlu K, Ayhan M. Comparative Assessment of Platinum Salts and Taxane Group Hypersensitivity Reactions, The Role of Skin Tests in Diagnosis? J Oncol Pharm Pract. 2021 Nov 30:10781552211050084. doi: 10.1177/10781552211050084.
• Tacar SY, Selcukbiricik F, Yilmaz M, Erturk K, Murat Sarici A, Gulturk I, Ayhan M, Tural D. Nivolumab for metastatic uveal melanoma: a multicenter, retrospective study. Melanoma Res. 2021 Oct 1;31(5):449-455. doi: 10.1097/CMR.0000000000000744.
• Özyurt E, Özçelik S, Sürmeli H, Çelik M, Ayhan M, Özçelik M. Side effects of immune-checkpoint inhibitors: Can multiple side effects be seen in a patient? J Oncol Pharm Pract. 2022 Mar;28(2):462-465. doi: 10.1177/10781552211038136.
• Dülgar Ö, Öven BB, Atcı MM, Arıkan R, Ay S, Ayhan M, Selvi O, Ozyukseler DT, Bayram E, Özcan E, Yasin Aİ, Gümüş M. Is the benefit of using adjuvant capecitabine in patients with residual triple-negative breast cancer related to pathological response to neoadjuvant chemotherapy? Expert Rev Anticancer Ther. 2022 Jul;22(7):773-780. doi: 10.1080/14737140.2022.2076670.
• Hizal M, Bilgin B, Paksoy N, Ayhan M, et all. The real-life efficacy and safety of osimertinib in pretreated advanced non-small cell lung cancer patients with T790M mutation: a Turkish Oncology Group Study. J Cancer Res Clin Oncol. 2022 Jun;148(6):1501-1508. doi: 10.1007/s00432-021-03748-7.
• Volume I, Kucukarda A, Atcı MM, Ayhan M, et all. Efficacy and safety of trastuzumab emtansine in older patients with HER2-positive advanced breast cancer: a real-world study. Tumori. 2022 Feb;108(1):19-25. doi: 10.1177/03008916211037739.
• Dogan I, Ayhan M, Gurbuz M, et all. The frequency and prognostic significance of ABO/Rh blood groups in male breast cancer patients: A multicenter study. Medicine (Baltimore). 2022 Sep 2;101(35):e30147. doi: 10.1097/MD.0000000000030147.
• Ozcelik M, Oyman A, Cil I, Duzgun O, Ozkan OF, Ayhan M. Cytoreductive Surgery versus Systemic Chemotherapy alone in Isolated Peritoneal Carcinomatosis of Colorectal Origin. J Coll Physicians Surg Pak. 2021 Nov;31(11):1308-1313. doi: 10.29271/jcpsp.2021.11.1308.
• Başoğlu T, Sakin A, Erol C, Ayhan M, et all. Real life experienceof patients with locally advanced gastric and gastroesophageal junction adenocarcinoma treated with neoadjuvant chemotherapy: a Turkish oncology group study. J Chemother. 2022 May 17:1-8. doi: 10.1080/1120009X.2022.2073159.
• Özdemir Ö, Zengel B, Yildiz Y, Ayhan M, et all. The effectiveness and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early-stage human epidermal growth factor receptor 2-positive breast cancer: Turkish Oncology Group study. Anticancer Drugs. 2022 Aug 1;33(7):663-670. doi: 10.1097/CAD.0000000000001310.
• Hizal M, Bilgin B, Paksoy N, Ayhan M, et all. The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification? (Turkish Oncology Group Study). J Cancer Res Clin Oncol. 2022 Sep 1. doi: 10.1007/s00432-022-04252-2.
• Hizal M, Bilgin B, Paksoy N, Ayhan M, et all. Real-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, ALK-positive non-small-cell lung cancer patients: a Turkish Oncology Group study. Future Oncol. 2022 Jul;18(23):2573-2582. doi: 10.2217/fon-2022-0083.
• Topcu A, Atci MM, Secmeler S, Besiroglu M, Ayhan M, Ozkan M, Bozkurt O, Urakci Z, Ay S, Geredeli C, Yasin AI, Turk HM. Efficacy of trastuzumab and potential risk factors on survival in patients with HER2-positive metastatic gastric cancer. Future Oncol. 2021 Nov;17(31):4157-4169. doi: 10.2217/fon-2021-0398.
• Bilgin B, Sendur MAN, Yucel S, Ayhan M, et all. Real-life comparison of the afatinib and first-generation tyrosine kinase inhibitors in nonsmall cell lung cancer harboring EGFR exon 19 deletion: a Turk Oncology Group (TOG) study. J Cancer Res Clin Oncol. 2021 Jul;147(7):2145-2152. doi: 10.1007/s00432-020-03501-6.
• Atci MM, Akagunduz B, Demir M, Arikan R, Ay S, Ozer M, Ayhan M, Cil I, Demir N, Ozyurt N, Karakaya G, Cevik GT, Onder AH, Selvi O, Sakin A. The impact of adjuvant oxaliplatin and tumor sidedness on the overall survival of stage IIB colon cancer patients: a multicentre study. J Chemother. 2023 Feb;35(1):19-28. doi: 10.1080/1120009X.2022.2040770.
• Tataroglu Ozyukseler D, Ay S, Turan M, Alkan G, Ayhan M, Surmeli H, et al. The Systemic Inflammation Response Index as a Prognostic Marker in Advanced Pancreatic Cancer. EJMI 2022;6(3):367–373.
• Yıldız F, Ayhan M, Demir H, et all. Comparing the efficacy of cabazitaxel in secondline and third-Line treatment of metastatic castration-resistant prostate cancer: a multi-center experience from Turkey. International Journal of Contemporary Medical Research, 7(9), 112-116.,Doi: 10.21276/ijcmr.2020.7.9.30
• Terzioğlu K, Ayhan M. Distribution of allergens detected on patch tests of patients with allergic contact dermatitis and investigation of their atopic background. Annals of Medical Research, 29(5), 422-426., doi: 10.5455/annalsmedres.2021.07.490
• Arikan R, Atci MM, Ay S, Ayhan M, et all Prognostic significance of mucinous histology in left sided metastatic colorectal cancers with wild type RAS and evaluation of backbone chemotherapy regimens. Oncol Lett. 2023 Apr 5;25(5):208. doi: 10.3892/ol.2023.13795.
• Almuradova E, Yalcin S, Arıkan R, Ayhan M, Demir H, Cevik GT, Karaca M, Petekkaya I, Karabulut B. Survival of Patients With Metastatic Rectum Cancer Who Underwent Metastasectomy Following Conversion Chemotherapy Sans Pelvic Radiotherapy: A Turkish Oncology Group Study. Cureus 2023 May 17;15(5):e39119. doi: 10.7759/cureus.39119.
• Topcu A, Besiroglu M, Atci MM, Ayhan M, et all. Second-line Therapy after Trastuzumab Failure in HER2-Positive Metastatic Gastric Cancer: A Real-life Data. EJMI 2023;7(2):153–161. DOI: 10.14744/ejmi.2023.22720
• Book Writing:
• Drug interactions and side effects of targeted agents, Section name: (Small molecule tyrosine kinase inhibitors; ROS-1 targeted therapies (Crizotinib, Seritinib)) (2021)., AYHAN MURAT, Turkish Clinics Journal of Medical Sciences, Editor: Mehmet Aliustaoglu, Publishing number:1, Number of Pages 92, ISBN:978-625-401- 466-6, Turkish
• Approach to gastrointestinal stromal tumors and neuroendocrine tumors, Department name: (Medical approach in primary non-gastrointestinal neuroendocrine tumors) (2020)., AYHAN MURAT, Akademisyen Yayınevi, Editor: Anılır Ender, Number of editions: 1, Number of Pages 382, ISBN: 9786052585719, Turkish
• Internal medicine emergencies, Department name: (Oncological emergencies) (2022)., YILDIRIM SEDAT, AYHAN MURAT, Efe Academic Publishing, Editor: Serdar Olt, Number of editions: 1, Number of Pages 232, ISBN: 978-625-8324-66- 2, Turkish
• Physicians' chemotherapy cancer drug manual 2020, Section name: (Common chemotherapy regimens in clinical practice) (2022)., SÜMBÜL AHMET TANER, ALKAN ALI, AKSOY ASUDE, AYHAN MURAT, et all, Türkiye Klinikleri Journal of Medical Sciences, Editor: EDWAR CHU, VINCENT T. DEVITA, SAADDETIN KILIÇKAP, CEMIL BILIR, SELÇUK SEBER, Number of editions: 1, Number of pages 772, ISBN: 978-625-401-290- 7, Turkish (Book Translation)

Dr. Turkan Ozturk Topcu is a clinical oncologist at Biruni University Hospital in Istanbul. She maintains professional ties with the MD Anderson Cancer Center in the USA. She specializes in the treatment of breast, lung, and gastrointestinal cancers. Dr. Topcu is a member of both ESMO and ASCO.

• Completed a fellowship at the Sunnybrook Odette Cancer Center Breast Clinic in Canada.
• Treats a wide range of conditions including liver, pancreatic, and gynecological cancers.
• Held clinical roles at major institutions like Moffitt Cancer Center in the USA.
• Works at Biruni University Hospital, a TEMOS-accredited facility in Turkey.

Dr. Orhan Tanriverdi is a urologist and surgical oncologist at Liv Hospital Ulus. He specializes in robot-assisted urologic surgery and uro-oncology. Dr. Tanriverdi treats prostate, bladder, kidney, and testicular cancers. He performs complex procedures including prostatectomy and nephrectomy. His practice is based at a JCI-accredited facility in Istanbul.

• Expertise in percutaneous kidney surgery and endourology.
• Authored over 50 national and international scientific publications.
• Member of the European Association of Urology and American Urological Association.
• Specialized in minimally invasive thyroid and laparoscopic surgery.

Dr. Ahmer Arif Shaikh is a surgical oncologist at HCG Manavata Cancer Centre. He specializes in oral cancer treatment with a focus on organ preservation. Dr. Shaikh completed fellowship training in head and neck surgical oncology at the same center. He is proficient in performing major maxillofacial and head and neck surgeries.

• Expert in functional rehabilitation for patients recovering from oral cancer.
• Active researcher with multiple publications in various medical journals.
• Works at an NABH-accredited center that treats over 75,000 patients yearly.
• Treats complex conditions including tongue, thyroid, and tonsil cancers.

Dr. Yogesh Batra heads the Gastroenterology and Hepatology Department at BLK Super Speciality Hospital. He is a recognized expert in treating viral hepatitis and complex liver conditions. Dr. Batra trained at AIIMS New Delhi, India’s top-ranked medical institute. He received the Young Investigator Award from the Indian Society of Gastroenterology.

• Winner of the Best Paper Award from the Indian Association for the Study of the Liver.
• Authored over 30 publications in national and international medical journals.
• Specializes in stomach, small intestine, and large bowel resections.
• Member of the Society of Gastrointestinal Endoscopy of India.

Dr. Raj Nagarkar has performed 50,000+ cancer surgeries. He leads surgical oncology at HCG Manavata Cancer Centre and specializes in thoracic procedures including lung biopsy.

• Completed surgical oncology residency at the prestigious Tata Memorial Hospital in Mumbai
• Holds an MRCS degree from the Royal College of Surgeons of Edinburgh
• Participated in 200+ clinical trials testing new protocols for cancer care
• Professor for DNB Superspecialty Surgical Oncology – trains future oncology surgeons
• Maintains membership with the Surgical Oncology Board of the Delhi National Board

Dr. Shaunak Valame is a medical oncologist at HCG Manavata Cancer Centre. He specializes in the molecular basis of lung cancer for targeted treatment.

• Earned his DNB in Medical Oncology at the prestigious Indraprastha Apollo Hospital
• Presented research at the American Society of Clinical Oncology symposium in San Francisco
• Delivered lectures for the International Winter School of Oncology at AIIMS Bhopal
• Maintains professional membership in the American Society of Clinical Oncology (ASCO)
• Supports lung biopsy diagnostics through detailed molecular mechanism evaluations

10,000 major surgeries performed – Dr. Lalit Banswal is a leading surgical oncologist at HCG Manavata Cancer Centre.

• Specializes in minimally invasive techniques for lung biopsy and tumor removal
• Trained at Tata Medical Centre – a premier institution for oncology
• Assistant Professor at the State Cancer Institute training the next generation
• Invited to lead research projects in gastrointestinal and surgical oncology
• Authored multiple papers in international journals on advanced surgical techniques

Dr. Shruti Kate is a lung cancer expert who presented research at the World Conference on Lung Cancer in Toronto. At HCG Manavata Cancer Centre, she uses lung biopsy results to guide advanced tumor treatments.

• Solo recipient of the Indian travel award at WCLC 2018 for her lung cancer research
• Former consultant at Tata Memorial Hospital – India's premier cancer research and treatment center
• Member of the International Association for the Study of Lung Cancer (IASLC)
• Heads the oncology department and specializes in treating solid lung tumors
• Expert in immunotherapy – uses the body's immune system to fight aggressive cancer cells

Dr. Chaitainya Borde has managed more than 30,000 PET scans. He leads nuclear medicine services at HCG Manavata Cancer Centre.

• Specializes in PET-CT scans to improve accuracy during a lung biopsy
• Proficient in all types of nuclear scans and cardiology services
• Authored several research papers published in medical journals
• Experienced in treating thyroid cancer with targeted radioiodine therapies

Dr. Sridhar P.S. is a radiation oncology expert at HCG Manavata Cancer Centre. He holds a Doctor of Medicine and a Diplomate of National Board in radiotherapy.

• Provides specialist oversight for lung biopsy procedures within oncological care
• Member of the Association of Radiation Oncology of India
• Belongs to the Society for Neuro-Oncology for specialized cancer insights
• Active member of the Indian Association of Hyperthermia Oncology
• Part of the Bangalore Oncology Group promoting high standards in cancer diagnostics

Professor Engin is the Director of Oncological Sciences at Medicana Bursa Hospital. He specializes in advanced lung tumor diagnostics and radiation therapies.

• Completed a post-doctoral fellowship in thermoradiotherapy at Thomas Jefferson University in the USA
• Conducted research on cancer risks at the American National Cancer Institute
• Former Chairman of Radiation Oncology at Uludağ University Medical College
• Expert in CyberKnife technology – a robotic system for pinpointing tumor locations
• Managed high-level oncological programs at Anadolu Medical Center for 13 years

Dr. Antonio Cubillo Gracián pioneered a liquid biopsy program in Spain for molecular tumor analysis. He is the Head of Medical Oncology at Hospital Universitario HM Sanchinarro.

• Specializes in stage 2–4 lung cancer diagnostics using molecular markers like EGFR and ALK
• Directs postgraduate research at HM CIOCC, focusing on new cancer therapies
• Designed targeted treatment plans based on genetic tumor features
• Leads clinical trials for new therapies through the Start Madrid program
• Associate Professor of Oncology at USP CEU – trains the next generation of specialists

Dr. Didem Tastekin is a medical oncologist at Biruni University Hospital in Istanbul. She specializes in breast and lung cancer treatment, including stage 4 cases. Dr. Tastekin received the TUBITAK Incentive Award for her work in cancer research. She is an active member of both ESMO and ASCO.

• Awarded Best Researcher of the Year at Istanbul University Oncology Institute.
• Treats complex cases at a TEMOS-accredited university hospital.
• Coordinates oncological check-ups and screenings for both men and women.
• Expert in diagnostics including PET-MRI, tumor markers, and organ biopsies.